Imaging of the Autonomic Nervous System: Focus on Cardiac Sympathetic Innervation

Seminars in Neurology

Volumn 23, Issue 4, 2003, Pages 423-433

  Goldstein, David S ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Autonomic failure; Dysautonomia; Multiple system atrophy; Norepinephrine; Parkinson's disease; Sympathetic

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123;

AUTONOMIC NERVOUS SYSTEM; CLINICAL FEATURE; CONFERENCE PAPER; HEART INNERVATION; HUMAN; ISOTOPE LABELING; NERVOUS SYSTEM FUNCTION; NEUROLOGIC DISEASE; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; SYMPATHETIC INNERVATION;

ADRENERGIC FIBERS; ANIMALS; AUTONOMIC NERVOUS SYSTEM; AUTONOMIC NERVOUS SYSTEM DISEASES; DIAGNOSTIC IMAGING; HEART; HUMANS;

EID: 1842459526     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-817726     Document Type: Conference Paper

References (115)

1. Goldstein D, Eisenhofer G, Robertson D, Straus R, Esler M. Dysautonomias: clinical disorders of the autonomic nervous system. Ann Intern Med 2002;137:753-763
2. Goldstein DS. The Autonomic Nervous System in Health and Disease. New York: Marcel Dekker, Inc; 2001
3. Pacak K, Palkovits M, Yadid G, Kvetnansky R, Kopin IJ, Goldstein DS. Heterogeneous neurochemical responses to different stressors: a test of Selye's doctrine of nonspecificity. Am J Physiol 1998;275:R1247-R1255
4. Young JB, Rosa RM, Landsberg L. Dissociation of sympathetic nervous system and adrenal medullary responses. Am J Physiol 1984;247:E35-E40
5. Oliver G, Schafer EA. On the physiological action of extract of the suprarenal capsules. J Physiol 1895;17:ix-xiv
6. Abel JJ, Crawford AC. On the blood-pressure-raising constituent of the suprarenal capsule. Bull Johns Hopkins Hosp 1897;8:151-157
7. Abel JJ. On a simple method of preparing epinephrin and its compounds. Bull Johns Hopkins Hosp 1902;13:29-36
8. Takamine J. The isolation of the active principle of the suprarenal gland. J Physiol 1901;27:30P-39P
9. Goldstein DS, Tack C. Non-invasive detection of sympathetic neurocirculatory failure. Clin Auton Res 2000;10:285-291
10. Bootsma M, Swenne CA, Van Bolhuis HH, Chang PC, Cats VM, Bruschke AV. Heart rate and heart rate variability as indexes of sympathovagal balance. Am J Physiol 1994;266:H1565-H1571
11. Grassi G, Esler M. How to assess sympathetic activity in humans. J Hypertens 1999;17:719-734
12. Hagbarth KE, Burke D. Microneurography in man. Acta Neurol (Napoli) 1977;32:30-34
13. Wallin BG, Elam M. Microneurography and autonomic dysfunction. In: Low PA, ed. Clinical Autonomic Disorders. Boston: Little, Brown; 1993:243-252
14. Dale HH. The action of certain esters and ethers of choline, and their relation to muscarine. J Pharmacol Exp Ther 1914;6:147-190
15. Loewi O, Navratil E. Uber humorale Ubertragbarkeit der Herzenvenwirkung. X. Mitteilung. Uber das Schicksal des Vagusstoffs. Pflugers Arch 1926;214:678-688
16. Ahlquist RP. A study of adrenotropic receptors. Am J Physiol 1948;153:586-600
17. Polinsky RJ, Kopin IJ, Ebert MH, Weise V. Pharmacologic distinction of different orthostatic hypotension syndromes. Neurology 1981;31:1-7
18. Bianchetti MG, Minder I, Beretta-Piccoli C, Meier A, Weidmann P. Effects of tyramine on blood pressure and plasma catecholamines in normal and hypertensive subjects. Klin Wochenschr 1982;60:465-470
19. Shannon JR, Flattem NL, Jordan J, et al. Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N Engl J Med 2000;342:541-549
20. Jordan J, Shannon JR, Black BK, et al. N(N)-nicotinic blockade as an acute human model of autonomic failure. Hypertension 1998;31:1178-1184
21. Goldstein DS, Grossman E, Listwak S, Folio CJ. Sympathetic reactivity during a yohimbine challenge test in essential hypertension. Hypertension 1991;18(Suppl. III):40-48
22. Charney DS, Heninger GR, Redmond DE Jr. Yohimbine induced anxiety and increased noradrenergic function in humans: effects of diazepam and clonidine. Life Sci 1983;33:19-29
23. Senard JM, Rascol O, Durrieu G, et al. Effects of yohimbine on plasma catecholamine levels in orthostatic hypotension related to Parkinson disease or multiple system atrophy. Clin Neuropharmacol 1993;16:70-76
24. Biaggioni I, Robertson RM, Robertson D. Manipulation of norepinephrine metabolism with yohimbine in the treatment of autonomic failure. J Clin Pharmacol 1994;34:418-423
25. Goldstein DS, Keiser HR. Pressor and depressor responses after cholinergic blockade in humans. Am Heart J 1984;107 (5 Pt 1):974-979
26. Bristow JD, Honour J, Pickering GW, Sleight P, Smyth HS. Diminished baroreflex sensitivity in high blood pressure. Circulation 1969;39:48-54
27. Cannon WB, de la Paz D. Emotional stimulation of adrenal gland secretion. Am J Physiol 1911;28:64-70
28. Cannon WB. The emergency function of the adrenal medulla in pain and in the major emotions. Am J Physiol 1914;33:356-372
29. Cannon WB. The interrelation of emotions as suggested by recent physiological researches. Am J Psychol 1914;25:256-282
30. Cannon WB, Rapport D. Further observations on the denervated heart in relation to adrenal secretion. Am J Physiol 1921;58:308-337
31. Goldstein DS, Feuerstein G, Izzo JL Jr, Kopin IJ, Keiser HR. Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man. Life Sci 1981;28:467-475
32. Holmes C, Eisenhofer G, Goldstein DS. Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl 1994;653:131-138
33. Eisenhofer G, Goldstein DS, Stull R, et al. Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clin Chem 1986;32:2030-2033
34. Kuwahara T, Hamada M, Hiwada K. Direct evidence of impaired cardiac sympathetic innervation in essential hypertensive patients with left ventricular hypertrophy. J Nucl Med 1998;39:1486-1491
35. Sakata K, Shirotani M, Yoshida H, Kurata C. Cardiac sympathetic nervous system in early essential hypertension assessed by 123I-MIBG. J Nucl Med 1999;40:6-11
36. Watanabe K, Sekiya M, Tsuruoka T, et al. Relationship between insulin resistance and cardiac sympathetic nervous function in essential hypertension. J Hypertens 1999;17:1161-1168
37. Ohya Y, Sasaki M, Fujishima S, et al. Myocardial imaging with 123I-metaiodobenzylguanidine in essential hypertension and renovascular hypertension. Clin Exp Hypertens 2001;23:293-304
38. Takahashi N, Nakagawa M, Saikawa T, et al. Effect of essential hypertension on cardiac autonomic function in type 2 diabetic patients. J Am Coll Cardiol 2001;38:232-237
39. Simula S, Vanninen E, Viitanen L, et al. Cardiac adrenergic innervation is affected in asymptomatic subjects with very early stage of coronary artery disease. J Nucl Med 2002;43:1-7
40. Agostini D, Lecluse E, Belin A, et al. Impact of exercise rehabilitation on cardiac neuronal function in heart failure: an iodine-123 metaiodobenzylguanidine scintigraphy study. Eur J Nucl Med 1998;25:235-241
41. Kurata C, Shouda S, Mikami T, et al. Metaiodobenzylguanidine and heart rate variability in heart failure. Jpn Circ J 1998;62:770-772
42. Atsumi H, Takeishi Y, Fujiwara S, Tomoike H. Cardiac sympathetic nervous disintegrity is related to exercise intolerance in patients with chronic heart failure. Nucl Med Commun 1998;19:451-456
43. Merlet P, Pouillart F, Dubois-Rande JL, et al. Sympathetic nerve alterations assessed with 123I-MIBG in the failing human heart. J Nucl Med 1999;40:224-231
44. Sakamaki F, Satoh T, Nagaya N, et al. Correlation between severity of pulmonary arterial hypertension and 123I-metaiodobenzylguanidine left ventricular imaging. J Nucl Med 2000;41:1127-1133
45. de Milliano PA, van Eck-Smit BL, van Zwieten PA, de Groot AC, Tijssen JG, Lie KI. Relationship between cardiac metaiodobenzylguanidine uptake and hemodynamic, functional and neurohormonal parameters in patients with heart failure. Eur J Heart Fail 2001;3:693-697
46. de Milliano PA, Tijssen JG, van Eck-Smit BL, Lie KI. Cardiac 123 I-MIBG imaging and clinical variables in risk stratification in patients with heart failure treated with beta blockers. Nucl Med Commun 2002;23:513-519
47. Takahashi N, Ishida Y, Maeno M, et al. Noninvasive identification of left ventricular involvements in arrhythmogenic right ventricular dysplasia: comparison of 123I-MIBG, 201TlCl, magnetic resonance imaging and ultrafast computed tomography Ann Nucl Med 1997;11:233-241
48. Yukinaka M, Nomura M, Ito S, Nakaya Y. Mismatch between myocardial accumulation of 123I-MIBG and 99mTc-MIBI and late ventricular potentials in patients after myocardial infarction: association with the development of ventricular arrhythmias. Am Heart J 1998;136:859-867
49. Nomura M, Nada T, Endo J, et al. Brugada syndrome associated with an autonomic disorder. Heart 1998;80:194-196
50. Schafers M, Wichter T, Lerch H, et al. Cardiac 123I-MIBG uptake in idiopathic ventricular tachycardia and fibrillation. J Nucl Med 1999;40:1-5
51. Okishige K, Sasano T, Yano K, Azegami K, Suzuki K, Itoh K. Serious arrhythmias in patients with apical hypertrophic cardiomyopathy Intern Med 2001;40:396-402
52. Wichter T, Matheja P, Eckardt L, et al. Cardiac autonomic dysfunction in Brugada syndrome. Circulation 2002;105:702-706
53. Nagaoka H, Iizuka T, Kubota S, et al. Depressed contractile response to exercise in diabetic patients in the absence of cardiovascular disease: relationship to adrenergic cardiac dysinnervation. Nucl Med Commun 1997;18:761-770
54. Ziegler D, Weise F, Langen KJ, et al. Effect of glycaemic control on myocardial sympathetic innervation assessed by [123I]metaiodobenzylguanidine scintigraphy: a 4-year prospective study in IDDM patients. Diabetologia 1998;41:443-451
55. Nagamachi S, Jinnouchi S, Kurose T, et al. 123I-MIBG myocardial scintigraphy in diabetic patients: relationship with 201Tl uptake and cardiac autonomic function. Ann Nucl Med 1998;12:323-331
56. Uehara A, Kurata C, Sugi T, Mikami T, Shouda S. Diabetic cardiac autonomic dysfunction: parasympathetic versus sympathetic. Ann Nucl Med 1999;13:95-100
57. Giordano A, Calcagni ML, Verrillo A, et al. Assessment of sympathetic innervation of the heart in diabetes mellitus using 123I-MIBG. Diabetes Nutr Metab 2000;13:350-355
58. Nagamachi S, Jinnouchi S, Kurose T, et al. Serial change in 123I-MIBG myocardial scintigraphy in non-insulin-dependent diabetes mellitus. Ann Nucl Med 2002;16:33-38
59. Hattori N, Rihl J, Bengel FM, et al. Cardiac autonomic dysinnervation and myocardial blood flow in long-term type 1 diabetic patients. Diabet Med 2003;20:375-381
60. Agostini D, Babatasi G, Manrique A, et al. Impairment of cardiac neuronal function in acute myocarditis: iodine-123-MIBG scintigraphy study. J Nucl Med 1998;39:1841-1844
61. Kakuchi H, Sasaki T, Ishida Y, Komamura K, Miyatake K. Clinical usefulness of 123I meta-iodobenzylguanidine imaging in predicting the effectiveness of beta blockers for patients with idiopathic dilated cardiomyopathy before and soon after treatment. Heart 1999;81:148-152
62. Toyama T, Aihara Y, Iwasaki T, et al. Cardiac sympathetic activity estimated by 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after beta-blocker or angiotensin-converting enzyme inhibitor therapy. J Nucl Med 1999;40:217-223
63. Momose M, Kobayashi H, Iguchi N, et al. Comparison of parameters of 123I-MIBG scintigraphy for predicting prognosis in patients with dilated cardiomyopathy. Nucl Med Commun 1999;20:529-535
64. Merlet P, Benvenuti C, Moyse D, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 1999;40:917-923
65. Maunoury C, Agostini D, Acar P, et al. Impairment of cardiac neuronal function in childhood dilated cardiomyopathy: an 123I-MIBG scintigraphic study. J Nucl Med 2000;41:400-404
66. Naruse H, Arii T, Kondo T, et al. Relation between myocardial response to dobutamine stress and sympathetic nerve activation in patients with idiopathic dilated cardiomyopathy: a comparison of 123I-MIBG scintigraphic and echocardiographic data. Ann Nucl Med 2000;14:427-432
67. Matsui T, Tsutamoto T, Kinoshita M. Relationship between cardiac 123I-metaiodobenzylguanidine imaging and the transcardiac gradient of neurohumoral factors in patients with dilated cardiomyopathy. Jpn Circ J 2001;65:1041-1046
68. Shimizu M, Ino H, Yamaguchi M, et al. Heterogeneity of cardiac sympathetic nerve activity and systolic dysfunction in patients with hypertrophic cardiomyopathy. J Nucl Med 2002;43:15-20
69. Matsui T, Tsutamoto T, Maeda K, Kusukawa J, Kinoshita M. Prognostic value of repeated 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments-comparison with neurohumoral factors. Circ J 2002;66:537-543
70. Kasama S, Toyama T, Hoshizaki H, et al. Dobutamine gated blood pool scintigraphy predicts the improvement of cardiac sympathetic nerve activity, cardiac function, and symptoms after treatment in patients with dilated cardiomyopathy. Chest 2002;122:542-548
71. Lanza GA. Abnormal cardiac nerve function in syndrome X. Herz 1999;24:97-106
72. Lanza GA, Giordano A, Pristipino C, et al. Relationship between myocardial 123I-metalodobenzylguanidine scintigraphic uptake and heart rate variability in patients with syndrome X. Ital Heart J 2000;1:221-225
73. Abe Y, Sugiura T, Takehana K, et al. Clinical significance of denervated but viable myocardium in patients with recanalized acute myocardial infarction. Nucl Med Commun 1999;20:727-735
74. Bengel FM, Barthel P, Matsunari I, Schmidt G, Schwaiger M. Kinetics of 123I-MIBG after acute myocardial infarction and reperfusion therapy. J Nucl Med 1999;40:904-910
75. Ando M, Yamabe H, Sakurai K, Kawai H, Yokoyama M. Relationship between cardiac sympathetic function and baro-receptor sensitivity after acute myocardial infarction. Circ J 2002;66:247-252
76. Soeki T, Tamura Y, Bandou K, et al. Long-term effects of the angiotensin-converting enzyme inhibitor enalapril on chronic heart failure. Examination by 123I-MIBG imaging. Jpn Heart J 1998;39:743-751
77. Sakata K, Shirotani M, Yoshida H, et al. Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. Hypertension 1999;33:1447-1452
78. Agostini D, Belin A, Amar MH, et al. Improvement of cardiac neuronal function after carvedilol treatment in dilated cardiomyopathy: a 123I-MIBG scintigraphic study. J Nucl Med 2000;41:845-851
79. Lotze U, Kaepplinger S, Kober A, Richartz BM, Gottschild D, Figulla HR. Recovery of the cardiac adrenergic nervous system after long-term beta-blocker therapy in idiopathic dilated cardiomyopathy: assessment by increase in myocardial 123I-metaiodobenzylguanidine uptake. J Nucl Med 2001;42:49-54
80. de Milliano PA, de Groot AC, Tijssen JG, van Eck-Smit BL, Van Zwieten PA, Lie KI. Beneficial effects of metoprolol on myocardial sympathetic function: evidence from a randomized, placebo-controlled study in patients with congestive heart failure. Am Heart J 2002;144:E3
81. Goldstein DS, Katzper M, Linares OA, Kopin IJ. Kinetic model for the fate of the sympathoneural imaging agent 6-[18F]fluorodopamine in the human heart: a novel means to assess cardiac sympathetic neuronal function. Naunyn Schmiedebergs Arch Pharmacol 2002;365:38-49
82. Shouda S, Kurata C, Mikami T, Wakabayashi Y. Effects of extrinsically elevated plasma norepinephrine concentration on myocardial 123I-MIBG kinetics in rats. J Nucl Med 1999;40:2088-2093
83. Senard JM, Rai S, Lapeyre-Mestre M, et al. Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;63:584-589
84. Micieli G, Martignoni E, Cavallini A, Sandrini G, Nappi G. Postprandial and orthostatic hypotension in Parkinson's disease. Neurology 1987;37:386-393
85. Anonymous. Cardiovascular disorders in Parkinson disease are underrated. Fortschr Neurol Psychiatr 1999;67:A8-A9
86. Hillen ME, Wagner ML, Sage JI. "Subclinical" orthostatic hypotension is associated with dizziness in elderly patients with Parkinson disease. Arch Phys Med Rehabil 1996;77:710-712
87. Gilman S, Low P, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. Clin Auton Res 1998;8:359-362
88. Mathias CJ. The classification and nomenclature of autonomic disorders-ending chaos, resolving conflict and hopefully achieving clarity. Clin Auton Res 1995;5:307-310
89. Goldstein DS, Polinsky RJ, Garty M, et al. Patterns of plasma levels of catechols in neurogenic orthostatic hypotension. Ann Neurol 1989;26:558-563
90. Goldstein DS, Holmes C, Sharabi Y, Brentzel S, Eisenhofer G. Plasma levels of catechols and metanephrines in neurogenic orthostatic hypotension. Neurology 2003;60:1327-1332
91. Polinsky RJ. Neuropharmacological investigation of autonomic failure. In: Bannister R, Mathias CJ, eds. Autonomic Failure. New York: Oxford University Press; 1992:334-358
92. Jordan J, Shannon JR, Biaggioni I, Norman R, Black BK, Robertson D. Contrasting actions of pressor agents in severe autonomic failure. Am J Med 1998;105:116-124
93. Hague K, Lento P, Morgello S, Caro S, Kaufmann H. The distribution of Lewy bodies in pure autonomic failure: autopsy findings and review of the literature. Acta Neuropathol (Berl) 1997;94:192-196
94. Orimo S, Oka T, Miura H, et al. Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy. J Neurol Neurosurg Psychiatry 2002;73:776-777
95. Black IB, Petito CK. Catecholamine enzymes in the degenerative neurological disease idiopathic orthostatic hypotension. Science 1976;192:910-912
96. Satoh A, Serita T, Tsujihata M. Total defect of metaiodobenzylguanidine (MIBG) imaging on heart in Parkinson's disease: assessment of cardiac sympathetic denervation. Nippon Rinsho 1997;55:202-206
97. Satoh A, Serita T, Seto M, et al. Loss of 123I-MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value. J Nucl Med 1999;40:371-375
98. Druschky A, Hilz MJ, Platsch G, et al. Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J Neurol Sci 2000;175:3-12
99. Braune S, Reinhardt M, Schnitzer R, Riedel A, Lucking CH. Cardiac uptake of [123I]MIBG separates Parkinson's disease from multiple system atrophy. Neurology 1999;53:1020-1025
100. Yoshita M, Hayashi M, Hirai S. Decreased myocardial accumulation of 123I-meta-iodobenzyl guanidine in Parkinson's disease. Nucl Med Commun 1998;19:137-142
101. Kanzaki N, Sato K, Hayabara T. Improved cardiac iodine-123 metaiodobenzylguanidine accumulation after drug therapy in a patient with Parkinson's disease. Clin Nucl Med 1997;22:697-699
102. Ohmura M. Loss of 123I-MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value. J Nucl Med 2000;41:1594-1595
103. Reinhardt MJ, Jungling FD, Krause TM, Braune S. Scintigraphic differentiation between two forms of primary dysautonomia early after onset of autonomic dysfunction: value of cardiac and pulmonary iodine-123 MIBG uptake. Eur J Nucl Med 2000;27:595-600
104. Braune S, Reinhardt M, Bathmann J, Krause T, Lehmann M, Lucking CH. Impaired cardiac uptake of meta-[123I]iodobenzylguanidine in Parkinson's disease with autonomic failure. Acta Neurol Scand 1998;97:307-314
105. Orimo S, Ozawa E, Oka T, et al. Different histopathology accounting for a decrease in myocardial MIBG uptake in PD and MSA. Neurology 2001;57:1140-1141
106. Senard JM, Brefel-Courbon C, Rascol O, Montastruc JL. Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging 2001;18:495-505
107. Takatsu H, Nishida H, Matsuo H, et al. Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG. J Nucl Med 2000;41:71-77
108. Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H. (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67:189-194
109. Yoshita M, Hayashi M, Hirai S. Iodine 123-labeled metaiodobenzylguanidine myocardial scintigraphy in the cases of idiopathic Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Rinsho Shinkeigaku 1997;37:476-482
110. Goldstein DS, Holmes C, Li ST, Bruce S, Metman LV, Cannon RO. Cardiac sympathetic denervation in Parkinson disease. Ann Intern Med 2000;133:338-347
111. Goldstein DS, Holmes C, Dendi R, Bruce S, Li S-T. Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology 2002;58:1247-1255
112. Li ST, Dendi R, Holmes C, Goldstein DS. Progressive loss of cardiac sympathetic innervation in Parkinson's disease. Ann Neurol 2002;52:220-223
113. Goldstein DS, Holmes C, Cannon RO III, Eisenhofer G, Kopin IJ. Sympathetic cardioneuropathy in dysautonomias. N Engl J Med 1997;336:696-702
114. Akincioglu C, Unlu M, Tunc T. Cardiac innervation and clinical correlates in idiopathic Parkinson's disease. Nucl Med Commun 2003;24:267-271
115. Taki J, Nakajima K, Hwang EH, et al. Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med 2000;27:566-573